Kexing Biopharm’s overseas commercial product
Recently, Kexing Biopharm announced that its overseas drug—Paclitaxel for Injection (Albumin-bound) (brand name: Apexelsin®)—has received marketing approval from the Philippine Food and Drug Administration.Compared with conventional paclitaxel injections and liposomal paclitaxel formulations, albumin-bound paclitaxel offers notable clinical advantages, including improved safety and better patient compliance. It has gained strong clinical...